代表性科研项目: |
主持项目: 1. 国家自然科学基金委员会, 青年科学基金项目, 82203980, TNKS1BP1通过BRCA1/BRCA2调控放射所致DNA损伤应答的机制研究, 2023-01-01至2025-12-31, 30万元,主持; 2. 吉林省教育厅科学技术研究项目, JJKH20241352KJ, TAB182调控EGFR影响放射致细胞DNA双链断裂修复的作用机制, 2024-01至 2025-12, 2.5万元,主持; 3. 吉林大学白求恩计划项目, 2020B03, AP-1-PARP1信号轴参与调控三阴性乳腺癌放疗抗性的分子机制研究, 2021-01至2022-12, 5万元,主持; 4. 中国博士后科学基金会, 博士后面上项目, 2021M693965, TAB182调控BRCA1影响细胞放射损伤和PARPi敏感性及机制, 2020-11至 2022-11, 8万元,主持; 5. 吉林大学海外博士B类人才启动项目,2020-2023,5万,主持; 主要参与项目: 1. 国家自然科学基金委员会, 面上项目, 82373666, miR-3656–Krüppel样因子10–IL-9与高血压微血管稀疏化的关联及作用机制研究, 2024-01-01至2027-12-31, 48万元,参与; 2. 国家自然科学基金委员会, 面上项目, 82173466, DNA-PKcs巴豆酰化修饰及其对DNA双链断裂修复功能的调节作用和机制研究, 2022-01-01至2025-12-31, 55万元,参与; 3. 瑞典Cancerfonden项目,Dnr4-51-2017, Genomic analyzes of Fra-1 function: from molecular mechanisms to triple-negative breast cancer therapy, 2017-01至2019-12, 240万瑞典克朗,参与; 4. 卡罗林斯卡医学院博士研究生项目,KID-2014VT (Dnr2-3707/2013), The estrogen receptor cistrome associated proteome; Possibilities to identify novel breast cancer drug targets, 2014-01至2018-01,108万瑞典克朗,参与。 |
代表性学术论文: |
[1]. Qin L, Liu R, Jia Z, Xu W, Wang L, Tian H, Lian X, Li W, Qi Y, He H*, Wang Z*. Multiple low-dose radiation ameliorates type-2 diabetes mellitus via gut microbiota modulation to activate TLR4/MyD88/NF-κB pathway. BMC Endocr Disord. 2025 Feb 7;25(1):32. [2]. Wang L, Li Z, He H, Qin L, Xu W, Tian H, Liu R, Lian X, Li W, Qi Y, Wang Z. Low-dose radiation ameliorates PM2.5-induced lung injury through non-canonical TLR1/TLR2-like receptor pathways modulated by Akkermansia muciniphila. Ecotoxicol Environ Saf. 2025 Jan 1;289:117625. [3]. He H, Wang S, Zhang W, Gao S, Guan H, Zhou P. Downregulation of TAB182 promotes cancer stem-like cell properties and therapeutic resistance in triple-negative breast cancer cells. BMC Cancer. 2023 Nov 13;23(1):1101. [4]. Song D*, He H*, Indukuri R, Huang Z, Stepanauskaite L, Sinha I, Haldosén LA, Zhao C, Williams C. ERα and ERβ Homodimers in the Same Cellular Context Regulate Distinct Transcriptomes and Functions. Front Endocrinol (Lausanne). 2022 Jul 6;13:930227. [5]. Song D, He H, Sinha I, Hases L, Yan F, Archer A, Haldosen LA, Zhao C, Williams C. Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor. Cancer Lett. 2021 May 28;506:23-34. [6]. He H, Song D, Sinha I, Hessling B, Li X, Haldosen LA, Zhao C. Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1. Oncogene. 2019 Jul;38(28):5725-5738. [7]. He H, Sinha I, Fan R, Haldosen LA, Yan F, Zhao C, Dahlman-Wright K. c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer. Oncogene. 2018 May;37(19):2586-2600. [8]. Qiao Y, He H, Jonsson P, Sinha I, Zhao C, Dahlman-Wright K. AP-1 Is a Key Regulator of Proinflammatory Cytokine TNFα-mediated Triple-negative Breast Cancer Progression. J Biol Chem, 2016 Mar 4;291(10):5068-79. [9]. He H, Zhen Q, Li Y, Kou CG, Tao YC, Wang C, Kanu JS, Lu YP, Yu MX, Zhang HP, Yu YQ, Li B, Liu YW. Prevalence of High Non-high-density Lipoprotein Cholesterol and Associated Risk Factors in Patients with Diabetes Mellitus in Jilin Province, China: A Cross-sectional Study. Biomed Environ Sci. 2016 Jul;29(7):534-8. [10].He H, Yu YQ, Li Y, Kou CG, Li B, Tao YC, Zhen Q, Wang C, Kanu JS, Huang XF, Han M, Liu YW. Dyslipidemia awareness, treatment, control and influence factors among adults in the Jilin province in China: a cross-sectional study. Lipids Health Dis. 2014 Aug 3; 13:122. 等SCI 15篇,中文核心期刊近10篇。 |